TH-302 in combination with radiotherapy enhances the therapeutic outcome and is associated with pretreatment [18F]HX4 hypoxia PET imaging

Clinical Cancer Research

Volumn 21, Issue 13, 2015, Pages 2984-2992

  Peeters, Sarah G J A ^a   Zegers, Catharina M L ^a   Biemans, Rianne ^a   Lieuwes, Natasja G ^a   Van Stiphout, Ruud G P M ^a   Yaromina, Ala ^a   Sun, Jessica D ^b   Hart, Charles P ^b   Windhorst, Albert D ^c   Van Elmpt, Wouter ^a   Dubois, Ludwig J ^a   Lambin, Philippe ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b Threshold Pharmaceuticals   (United States)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOGEN; EVOFOSFAMIDE; FLORTANIDAZOLE F 18; NICOTINAMIDE; PIMONIDAZOLE; ANTINEOPLASTIC AGENT; HX4 COMPOUND; IMIDAZOLE DERIVATIVE; NITROIMIDAZOLE DERIVATIVE; PHOSPHORAMIDE MUSTARD; RADIOPHARMACEUTICAL AGENT; TRIAZOLE DERIVATIVE;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER RADIOTHERAPY; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; HYPOXIA; HYPOXIC FRACTION; MOUSE; NON SMALL CELL LUNG CANCER; NONHUMAN; ONCOLOGICAL PARAMETERS; OXYGEN BREATHING; OXYGEN THERAPY; OXYGENATION; PET SCANNER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIATION DOSE; RAT; RHABDOMYOSARCOMA; THERAPY EFFECT; TREATMENT OUTCOME; TUMOR GROWTH; TUMOR VOLUME; TUMOR XENOGRAFT; ANIMAL; CARCINOMA, NON-SMALL-CELL LUNG; CELL HYPOXIA; CHEMORADIOTHERAPY; DRUG SCREENING; LUNG NEOPLASMS; SCINTISCANNING;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CELL HYPOXIA; CHEMORADIOTHERAPY; IMIDAZOLES; LUNG NEOPLASMS; NITROIMIDAZOLES; PHOSPHORAMIDE MUSTARDS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RATS; TREATMENT OUTCOME; TRIAZOLES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84941985206     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-15-0018     Document Type: Article

References (32)

1. Horsman MR, Mortensen LS, Petersen JB, Busk M, Overgaard J. Imaging hypoxia to improve radiotherapy outcome. Nature reviews Clinical oncology 2012;9:674-87.
2. Vaupel P, Mayer A. Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev 2007;26:225-39.
3. Sun JD, Liu Q, Wang J, Ahluwalia D, Ferraro D, Wang Y, et al. Selective tumor hypoxia targeting by hypoxia-activated prodrug TH-302 inhibits tumor growth in preclinical models of cancer. Clin Cancer Res 2012; 18:758-70.
4. Liu Q, Sun JD, Wang J, Ahluwalia D, Baker AF, Cranmer LD, et al. TH-302, a hypoxia-activated prodrug with broad in vivo preclinical combination therapy efficacy: optimization of dosing regimens and schedules. Cancer Chemother Pharmacol 2012;69:1487-98.
5. Weiss GJ, Infante JR, Chiorean EG, Borad MJ, Bendell JC, Molina JR, et al. Phase 1 study of the safety, tolerability, and pharmacokinetics of TH-302, a hypoxia-activated prodrug, in patients with advanced solid malignancies. Clin Cancer Res 2011;17:2997-3004.
6. Ganjoo KN, Cranmer LD, Butrynski JE, Rushing D, Adkins D, Okuno SH, et al. A phase I study of the safety and pharmacokinetics of the hypoxiaactivated prodrug TH-302 in combination with doxorubicin in patients with advanced soft tissue sarcoma. Oncology 2011;80:50-6.
7. Chawla SP, Cranmer LD, Van Tine BA, Reed DR, Okuno SH, Butrynski JE, et al. Phase II study of the safety and antitumor activity of the hypoxiaactivated prodrug TH-302 in combination with doxorubicin in patients with advanced soft tissue sarcoma. J Clin Oncol 2014;32:3299-306.
8. Borad MJ, Reddy SG, Bahary N, Uronis HE, Sigal D, Cohn AL, et al. Randomized Phase II Trial of Gemcitabine Plus TH-302 Versus Gemcitabine in Patients With Advanced Pancreatic Cancer. J Clin Oncol 2014 Dec 15. [Epub ahead of print].
9. Dubois LJ, Lieuwes NG, JanssenMH, Peeters WJ,Windhorst AD, Walsh JC, et al. Preclinical evaluation and validation of [18F]HX4, a promising hypoxia marker for PET imaging. Proc Natl Acad Sci U S A 2011;108: 14620-5.
10. Zegers CM, van Elmpt W, Wierts R, Reymen B, Sharifi H, Ollers MC, et al. Hypoxia imaging with [(1)(8)F]HX4 PET in NSCLC patients: defining optimal imaging parameters. Radiother Oncol 2013;109:58-64.
11. Zegers CM, van Elmpt W, Reymen B, Even AJ, Troost EG, Ollers MC, et al. In vivo quantification of hypoxic and metabolic status of NSCLC tumors using [18F]HX4 and [18F]FDG-PET/CT imaging. Clin Cancer Res 2014;20: 6389-97.
12. RischinD,Hicks RJ, Fisher R, Binns D, Corry J, Porceddu S, et al. Prognostic significance of [18F]-misonidazole positron emission tomographydetected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with or without tirapazamine: a substudy of Trans-Tasman Radiation Oncology Group Study 98.02. J Clin Oncol 2006;24:2098-104.
13. Peeters SG, Zegers CM, Lieuwes NG, van Elmpt W, Eriksson J, van Dongen GA, et al. A comparative study of the hypoxia PET tracers [18F]HX4, [18F] FAZA, and [18F]FMISOin a preclinical tumor model. Int J Radiat Oncol Biol Phys 2015;91:351-9.
14. van Loon J, JanssenMH,OllersM, AertsHJ, Dubois L,HochstenbagM, et al. PET imaging of hypoxia using [18F]HX4: a phase I trial. Eur J NuclMedMol Imaging 2010;37:1663-8.
15. Dubois L, Landuyt W, Haustermans K,Dupont P, Bormans G, Vermaelen P, et al. Evaluation of hypoxia in an experimental rat tumour model by [(18) F]fluoromisonidazole PET and immunohistochemistry. Br J Cancer 2004;91:1947-54.
16. Edelstein A, Amodaj N, Hoover K, Vale R, Stuurman N. Computer control of microscopes using microManager. Curr Protoc Mol Biol 2010;Chapter 14:Unit14 20.
17. Jung D, Lin L, Jiao H, Cai X, Duan JX, Matteucci M. Pharmacokinetics of TH- 302: a hypoxically activated prodrug of bromo-isophosphoramide mustard in mice, rats, dogs and monkeys. Cancer Chemother Pharmacol 2012;69:643-54.
18. Wilson WR, Hay MP. Targeting hypoxia in cancer therapy. Nat Rev Cancer 2011;11:393-410.
19. Fass L. Imaging and cancer: a review. Mol Oncol 2008;2:115-52.
20. Orloff J, Douglas F, Pinheiro J, Levinson S, Branson M, Chaturvedi P, et al. The future of drug development: advancing clinical trial design. Nat Rev Drug Discov 2009;8:949-57.
21. Hill RP, Bush RS, Yeung P. The effect of anaemia on the fraction of hypoxic cells in an experimental tumour. Br J Radiol 1971;44:299-304.
22. Stanley JA, Shipley WU, Steel GG. Influence of tumour size on hypoxic fraction and therapeutic sensitivity of Lewis lung tumour. Br J Cancer 1977;36:105-13.
23. Wouters BG, Brown JM. Cells at intermediate oxygen levels can be more important than the "hypoxic fraction" in determining tumor response to fractionated radiotherapy. Radiat Res 1997;147:541-50.
24. Horsman MR, Overgaard J. Preclinical studies on how to deal with patient intolerance to nicotinamide and carbogen. Radiother Oncol 2004;70:301-9.
25. Troost EG, Laverman P, Kaanders JH, Philippens M, Lok J, Oyen WJ, et al. Imaging hypoxia after oxygenation-modification: comparing [18F]FMISO autoradiography with pimonidazole immunohistochemistry in human xenograft tumors. Radiother Oncol 2006;80:157-64.
26. Hou H, Dong R, Lariviere JP, Mupparaju SP, Swartz HM, Khan N. Synergistic combination of hyperoxygenation and radiotherapy by repeated assessments of tumor pO2 with EPR oximetry. J Radiat Res 2011;52:568-74.
27. KhanN, LiH, Hou H, Lariviere JP,Gladstone DJ,Demidenko E, et al. Tissue pO2 of orthotopic 9L and C6 gliomas and tumor-specific response to radiotherapy and hyperoxygenation. Int J Radiat Oncol Biol Phys 2009; 73:878-85.
28. Martin L, Lartigau E, Weeger P, Lambin P, LeRidant AM, Lusinchi A, et al. Changes in the oxygenation of head and neck tumors during carbogen breathing. Radiother Oncol 1993;27:123-30.
29. Janssens GO, Rademakers SE, Terhaard CH, Doornaert PA, Bijl HP, van den Ende P, et al. Accelerated radiotherapywith carbogen and nicotinamide for laryngeal cancer: results of a phase III randomized trial. J Clin Oncol 2012;30:1777-83.
30. Schuuring J, Bussink J, Bernsen HJ, Peeters W, van der Kogel AJ. Effect of carbogen breathing on the radiation response of a human glioblastoma xenograft: analysis of hypoxia and vascular parameters of regrowing tumors. Strahlenther Onkol 2006;182:408-14.
31. Bentzen SM, Gregoire V. Molecular imaging-based dose painting: a novel paradigm for radiation therapy prescription. Semin Radiat Oncol 2011; 21:101-10.
32. Lambin P, van Stiphout RG, Starmans MH,Rios-Velazquez E, Nalbantov G, Aerts HJ, et al. Predicting outcomes in radiation oncology-multifactorial decision support systems. Nat Rev Clin Oncol 2013;10:27-40.